Singapore, July 9 -- The Serum Institute of India (SII) and the non-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) have signed a licensing agreement covering clinical testing and future access for an SII-developed monoclonal antibody treatment (formerly known as VIS513) against dengue.

With this agreement finalised, a Phase III clinical trial led by DNDi is expected to begin in the first quarter of 2027 across Malaysia, Thailand, and Brazil, all home to leading public health institutions that are members of the Dengue Alliance, a global partnership of dengue-endemic countries working to develop effective and accessible treatments. 1,000 participants are expected to join the study across the three coun...